Related Experiment Video
Updated: Jan 2, 2026

Guidelines for Elective Pediatric Fiberoptic Intubation
Published on: January 17, 2011
Dosing of Continuous Fentanyl Infusions in Obese Children: A Population Pharmacokinetic Analysis
Anil R Maharaj1, Huali Wu1, Kanecia O Zimmerman1,2
1Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA.
Insights
This study developed a population pharmacokinetic model for fentanyl in obese children, finding a model-based infusion strategy improves target concentration achievement. This research is crucial for optimizing pediatric pain management.
Area of Science:
- Pharmacology
- Pediatric Anesthesiology
- Pharmacometrics
Background:
- Fentanyl pharmacokinetics (PK) differences between obese and nonobese adults are known, but data on childhood obesity's impact is limited.
- Understanding fentanyl PK in obese children is critical for safe and effective pain management.
Purpose of the Study:
- To develop a population pharmacokinetic (PopPK) model for fentanyl in a cohort of predominantly obese children.
- To evaluate continuous infusion strategies for achieving target steady-state fentanyl concentrations (Css) within an analgesic range (1-3 ng/mL).
Main Methods:
- A PopPK model was developed using 53 samples from 32 children (94% obese).
- A 2-compartment model, allometrically scaled by total body weight, was used.
- A probability-based approach assessed different infusion strategies.
Main Results:
- The model indicated typical fentanyl clearance of 32.5 L/h (scaled to 70 kg).
- A fixed dose infusion (1 µg/kg/h) showed variable success in reaching target Css, with increased risk of exceeding 3 ng/mL in heavier children.
- A proposed model-based strategy improved consistent achievement of target Css across varying body weights.
Conclusions:
- Allometric scaling of clearance by weight is appropriate for intravenous fentanyl PK in obese children.
- The developed model-derived infusion strategy optimizes fentanyl dosing to maximize the probability of achieving therapeutic concentrations in pediatric patients of diverse weights.
Abstract:
Differences in fentanyl pharmacokinetics (PK) between obese and nonobese adults have previously been reported; however, the impact of childhood obesity on fentanyl PK is relatively unknown. We developed a population pharmacokinetic (PopPK) model using opportunistically collected samples from a cohort of predominately obese children receiving fentanyl per the standard of care. Using a probability-based approach, we evaluated the ability of different continuous infusion strategies to provide steady-state concentrations (Css ) within an analgesic concentration range (1-3 ng/mL). Fifty-three samples from 32 children were used for PopPK model development. Median (range) age and body weight of study participants were 13 years (2-19 years) and 52 kg (16-164 kg), respectively. The majority of children (94%) were obese. A 2-compartment model allometrically scaled by total body weight provided an appropriate fit to the data. Estimated typical clearance was 32.5 L/h (scaled to 70 kg). A fixed dose rate infusion of 1 µg/kg/h was associated with probabilities between 49% and 58% for achieving Css within target; however, the risk of achieving Css > 3 ng/mL increased with increasing body weight (15% at 16 kg vs 43% at 164 kg). A proposed model-based infusion strategy maintained consistent probabilities across the examined weight range for achieving Css within (58%) and above (20%) target. Use of an allometric relationship between weight and clearance was appropriate for describing the PK of intravenous fentanyl in our cohort of predominately obese children. Our proposed model-derived continuous infusion strategy maximized the probability of achieving target Css in children of varying weights.
Related Concept Videos
Drug Dosing: Obese Patients
Drug Dosing: Infants and Children
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Pharmacokinetics in Pediatric Patients: Drug Distribution
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

